## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T110841 | Somewhat-Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI Models-as-a-Service, to integrate AI into lab workflows for molecular and materials design, aiming to enhance its software revenue growth story. This platform is critical for Revvity's long-term strategy to build a high-quality, software-heavy earnings base, despite ongoing pressures in its legacy diagnostics business. The move reinforces Revvity's investment narrative focused on high-margin software capabilities.

**2. (RVTY) as a Liquidity Pulse for Institutional Tactics**
- Source: Stock Traders Daily | 20251222T205000 | Bearish | Relevance: 100%
- This article provides an institutional market analysis for Revvity Inc. (NASDAQ: RVTY), highlighting weak sentiment across all horizons and suggesting a short bias. It details an exceptional 39.6:1 risk-reward short setup and offers three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating weak signals across near-term, mid-term, and long-term horizons, accompanied by support and resistance levels.

**3. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T112310 | Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI-powered platform for molecular and materials design, aiming to integrate AI directly into laboratory workflows. This move reinforces Revvity's strategy to shift towards higher-margin, software-enabled tools, offsetting pressures in legacy diagnostics and supporting recurring digital revenue. Despite the promising AI advancements, the company still faces risks from tightening reimbursement policies and pricing pressure in diagnostics, with its long-term financial health depending on a balance between AI investments and capital returns.

**4. Revvity introduces AI-augmented design platform for molecular and materials discovery**
- Source: BioSpectrum India | 20251222T074102 | Bullish | Relevance: 100%
- Revvity, Inc. has announced Signals Xynthetica™, an AI-augmented design platform for molecular and materials discovery. This platform integrates in-silico generation, predictive modeling, and experimental validation, allowing scientific teams to iteratively refine candidate molecules. Signals Xynthetica aims to bridge the gap between powerful AI models and real-world experimental data, providing a Models-as-a-Service (MaaS) offering to streamline the application and governance of predictive models in scientific research.

**5. Stocks making the biggest moves midday: Novo Nordisk, ServiceNow, Freeport-McMoRan, Structure Therapeutics & more**
- Source: CNBC | 20251223T170828 | Bullish | Relevance: 60%
- Major stock movements midday included Novo Nordisk surging 8% after its GLP-1 pill received FDA approval, impacting other obesity drug developers positively. ServiceNow fell nearly 3% following its announcement to acquire cybersecurity startup Armis for $7.75 billion. Mining stocks, including Freeport McMoRan, rallied as gold, silver, and copper prices hit record highs, while crypto-linked stocks dipped due to stronger-than-anticipated GDP figures cooling Federal Reserve rate cut expectations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.3x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.3 |
| Current P/E | 19.7 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 5.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 46. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.85% (CS: 13) | Weak |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.022x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.79
- **Stop Loss:** $91.23 (5.7% risk)
- **Target:** $102.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 215
- **Position Value:** $20,809.85
- **Portfolio %:** 20.81%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*